The thrombogenicity of 6-azauridine

S. N. Gitel, A. J. Grieco, S. Wessler, S. E. Snyderman

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The antimetabolite 6-azauridine blocks the de novo synthesis of pyrimidines and causes increased serum levels of several amino acids including homocystine. 6-Azauridine was withdrawn from clinical use for the treatment of psoriasis because of the occurrence of arterial and venous thromboembolic episodes in some psoriatic patients. Utilizing a standard animal model for the recognition of venous and arterial thrombosis, 6-azauridine was demonstrated in this study to cause thrombosis without producing homocystinemia when administered orally or intravenously.

Original languageEnglish
Pages (from-to)54-57
Number of pages4
Issue number1
StatePublished - 1979
Externally publishedYes


Dive into the research topics of 'The thrombogenicity of 6-azauridine'. Together they form a unique fingerprint.

Cite this